Recreational cannabis use: Pleasures and pitfalls

Rella, Joseph G.

doi:10.3949/ccjm.82a.14073

Cited by 15 publications

(19 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though acute psychoactive effects of cannabis vary widely, individuals use cannabis most commonly for its euphoric and calming effects (Rella, 2015). Use of cannabis may elevate mood and improve sleep for some individuals, at least in the short-term (Buckner et al, 2015; Whiting et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life

Hser

Mooney

Huang

et al. 2017

Journal of Substance Abuse Treatment

View full text Add to dashboard Cite

Aims This study examined the longitudinal association between reductions in cannabis use and changes in anxiety, depression, sleep quality, and quality of life. Methods Secondary analyses were conducted based on data from a cannabis use disorder medication trial in 302 adults (ages 18–50). Changes in symptoms of anxiety and depression, sleep quality, and quality of life were assessed in relation to changes in cannabis use during the 12-week trial of treatment. Results Based on the slope of individual cannabis use trajectory, the sample was classified into two groups (Cannabis Use Reduction, n=152 vs. Cannabis Use Increase, n=150) which was included as a binary covariate in subsequent modeling. Controlling for demographics (age, gender, race/ethnicity), treatment condition, and time-varying tobacco and alcohol use, separate latent growth curve models showed a significant association between the Cannabis Use Reduction group and improvement (i.e., lower values in slope) in anxiety (β= −.09, SE=0.04; p<0.05), depression (β= −0.11, SE=0.04; p<0.01), and sleep quality (β= −0.07, SE=0.03; p<0.05) over the observation period, but not in quality of life. Conclusions These results indicate a longitudinal relationship between reductions in cannabis use and improvements in anxiety, depression, and sleep quality. Clinicians treating patients with co-occurring cannabis use and problems with anxiety, depression, or sleep quality should attend to cannabis use reduction as a component of treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life

Hser

Mooney

Huang

et al. 2017

Journal of Substance Abuse Treatment

View full text Add to dashboard Cite

show abstract

“…Parallel to this increase, frequency of previously unexpected complications and symptoms among these cases have also increased. Synthetic cannabinoids have become the most frequently used illegal substance worldwide with an estimated number of 160 million users 5 . As it is possible to make changes in their chemical composition, various combinations of SCs may arise.…”

Section: Discussionmentioning

confidence: 99%

“…Although SCs are usually smoked in the form of cigarette (pipe, through smoking or hookah), its use through evaporation, oral or rectal use are also reported 5 . Parenteral use of SCs has not been reported yet.…”

Section: Discussionmentioning

confidence: 99%

“…However, after oral use, there can be a delay in the onset of action depending upon food intake, digestion activity and the changes in the first pass effect 5,8 . The lipophilic nature of SCs causes storage in the fatty tissue, showing a biphasic effect and the gradual elimination after their consumption 5 . The way that our patients inhale the substance was in the form of smoking.…”

Section: Discussionmentioning

confidence: 99%

“…Effects of SCs immediately starts as they are easily absorbed from the airway. They decrease intraocular pressure and cause conjunctival hyperemia 5 . Besli et al 7 have reported conjunctival hyperemia in a rate of 87.5% in adult patients.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A new emerging problem in pediatric emergency units: Synthetic cannabinoids

Aladağ-Çiftdemir¹,

Yücel²,

Duran³

et al. 2016

Turk J Pediatr

View full text Add to dashboard Cite

Synthetic cannabinoids or synthetic marijuana derivatives known as "Bonzai" in Turkey are addictive substances that affect the brain and have serious side effects. In recent years, the use of these substances has also been increasing in our country as well as all over the world. These substances present with various names and brands, the most common names in Turkey are "Bonzai" and "Jamaika". In this study, we aimed to evaluate the demographic and clinical findings of these patients. We retrospectively evaluated patients admitted to our pediatric emergency department between March 2013 and March 2015 due to the complaints developing after the use of "Bonzai" in terms of age, gender, admission date, complaint, clinical findings, laboratory findings, consuming method of the substance, additional substance use, observation durations, hospitalization status and mortality rates. The most common complaint was faintness and drowsiness. Changes in the state of consciousness, tachycardia, hypertension were the most common clinical findings. Most common consuming method of the drug was in the form of smoking. The rate of "Bonzai" use among adolescents is increasing every day. Physicians in emergency departments should be educated on this issue and it must be kept in mind that most of the patients admitted are with complaints related to changes in the cognitive state (of consciousness) but they can also apply with complaints about all other systems.

show abstract